Stockreport

Immunovant shares plunge after phase 3 trials fails to meet primary endpoint [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF two Phase 3 trials evaluating batoclimab as a treatment for thyroid eye disease (TED) both failed to meet their primary endpoint. The studies, known as the GO trials, [Read more]